EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Opportunities and challenges for countermeasures against Rift Valley fever virus: A quintessential One Health pathogen

Brian E Dawes iD, Keli N Gerken, Bernard Bett, A Desiree LaBeaud

PLOS Neglected Tropical Diseases · 17.08.2026 · 20 (8) · e0014645

DOI: 10.1371/journal.pntd.0014645 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 17.08.2026. Verfasst von Brian E Dawes und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, United…. Hauptthemen laut MEDLINE: Rift Valley Fever, Rift Valley fever virus, One Health. Die Arbeit nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rift Valley fever virus (RVFV) is a zoonotic arbovirus transmitted by a wide range of mosquito vectors present across the African continent. RVFV has resulted in large-scale epidemics in East, West, southern, and northern Africa with additional epidemics affecting the Arabian Peninsula, Mayotte, and Comoros. In some areas, rather than large-scale isolated outbreaks, RVFV causes a fluctuating low-level endemic burden affecting livestock populations by resulting in pregnancy loss and significant production losses. RVFV risk extends into the human population when it is transmitted either by vector-borne transmission or direct contact with infected animals or animal products such as blood, meat, or milk. Following infection, 2%–3% of humans can develop severe disease manifestations including encephalitis/meningitis, hemorrhagic fever, and retinitis, with visual deficits commonly reported among survivors. While RVF cases in animals and humans have been spatially linked, the proportion and risk associated with spillover events is poorly classified. Given RVFV’s dual threat to human and livestock health, it has been designated a priority pathogen by WHO for development of countermeasures. This review aims to summarize current knowledge of RVFV epidemiology, infection, and control as well as highlight key recent advances in the understanding of epidemiology and vaccine development. Multiple next-generation vaccine candidates have advanced to phase two clinical trials which offer hope for approved and commercially available human vaccines in the coming decades. However, despite these promising advancements, key gaps in knowledge remain, particularly regarding the total burden and geographic distributions of endemic and epidemic infections, shifting epidemiologic patterns, optimal vaccine use cases, and the effects of RVFV infection on pregnancy in humans living in hyperendemic regions. Many gaps in understanding persist, and RVFV remains a quintessential One Health pathogen requiring coordinated human, animal, and environmental investigation and collaboration to translate scientific advances into effective national public health strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rift Valley FeverRift Valley fever virusOne HealthHumansAnimalsZoonosesAfricaMosquito VectorsLivestockViral VaccinesFemale

Substanzen

Viral Vaccines

Autor:innen und Institutionen

  • Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, United States of America.
  • Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, United Kingdom.
  • International Livestock Research Institute, Nairobi, Kenya.
  • Infectious Disease Epidemiology, Wageningen University and Research, Wageningen, The Netherlands.
  • Division of Pediatric Infectious Diseases, Department of Pediatrics, Stanford University School of Medicine, Stanford, California, United States of America.

ORCID-Profile: Brian E Dawes

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Dawes, B. E., Gerken, K. N., Bett, B., & LaBeaud, A. D. (2026). Opportunities and challenges for countermeasures against Rift Valley fever virus: A quintessential One Health pathogen. PLOS Neglected Tropical Diseases, 20(8), e0014645. https://doi.org/10.1371/journal.pntd.0014645

Vancouver

Dawes BE, Gerken KN, Bett B, LaBeaud AD. Opportunities and challenges for countermeasures against Rift Valley fever virus: A quintessential One Health pathogen. PLOS Neglected Tropical Diseases. 2026;20(8):e0014645. doi:10.1371/journal.pntd.0014645

BibTeX
@article{Dawes2026,
  author = {Dawes, Brian E and Gerken, Keli N and Bett, Bernard and LaBeaud, A Desiree},
  title = {Opportunities and challenges for countermeasures against Rift Valley fever virus: A quintessential One Health pathogen},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2026},
  volume = {20},
  number = {8},
  pages = {e0014645},
  doi = {10.1371/journal.pntd.0014645}
}
Kostenlos starten →